Source: Eur Respir J 2007; 30: 26-30
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tiev K. P., Cabane J., Aubourg F., Kettaneh A., Ziani M., Mouthon L., Duong-Quy S., Fajac I., Guillevin L., Dinh-Xuan A. T.. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007; 30: 26-30

Member's Comments

No comment yet.

Related content which might interest you: An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis Source: Eur Respir J 2004; 24 : 609-614 Year: 2004 Increased alveolar concentrations of exhaled nitric oxide (NO) are associated with lung affection in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005 Bronchial and alveolar exhaled nitric oxide as a marker of systemic involvement in patients with Crohn‘s disease Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Elevated levels of alveolar nitric oxide in patients with inflammatory bowel disease Source: International Congress 2016 – Airway biomarkers Year: 2016 Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients Source: Eur Respir J 2009; 34: 138-144 Year: 2009 Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease Source: International Congress 2017 – ILDs: clinical problems Year: 2017 The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Fractional exhaled nitric oxide for eosinophilic inflammation in stable COPD Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017 Exhaled nitric oxide levels in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Nasal nitric oxide Source: Eur Respir Monogr 2010; 49: 71-81 Year: 2010 Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients Source: Eur Respir J 2001; 17: 1267-1270 Year: 2001 Fractional exhaled nitric oxide levels in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity Year: 2016 Clinical correlates of alveolar nitric oxide in COPD Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Exhaled nitric oxide is not reduced in infants with cystic fibrosis Source: Eur Respir J 2006; 27: 350-354 Year: 2006 Exhaled nitric oxide increases in chronic eosinophilic pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 509s Year: 2002 Exhaled nitric oxide and pulmonary function in children with sickle cell disease Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management Year: 2010 Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model Source: Eur Respir J 2006; 28: 1236-1244 Year: 2006